August 25, 2023 – Potentially modifiable comorbid conditions and complications have a major impact on the risks of total hip arthroplasty (THA) for people in their nineties, reports a study in The Journal of Bone & Joint Surgery. The journal is published in the Lippincott portfolio in partnership with Wolters Kluwer.
Patients ³90 years old have higher complication and mortality rates following THA, as compared with younger patients. But while age is a significant factor, the risks associated with THA in nonagenarians are largely related to the patient's overall health and fitness for surgery, according to the new research by Dr Vincent J. Leopold, MD, and colleagues of the Charité-University Hospital Berlin.
New data on safety of THA at age 90 or older
With the aging of the population, there is ongoing debate regarding the safety of THA in the oldest age groups. While some studies have found no increase in complications following THA for nonagenarians, others have reported that the risk of complications increases with age.
Dr. Leopold and colleagues analyzed the characteristics and outcomes of 263,967 patients ³60 years old who underwent THA between 2012 and 2021. Of these, 1,859 patients – 0.7% of the total – were in their nineties. The analysis focused on how patient age and health status affected the risks of complications and death associated with THA.
Overall, nonagenarians had higher complication and mortality rates compared with younger age groups. Major complications occurred in 19.9% of patients in their nineties, compared with 10.7% for patients in their eighties, 6.2% in their seventies, and 3.7% in their sixties. Common major complications included acute kidney failure, delirium, and blood clotting abnormalities.
Rate of minor complications also increased with age – up to 62.7% for nonagenarians. Patients in their nineties also had the highest mortality rate: 26.5%, compared to 11.8% for patients in their eighties, 6.0% in their seventies, and 2.8% in their sixties.
Comorbidity has major impact on THA risks
While age itself was an independent risk factor, the increased risks in nonagenarians were strongly associated with the presence of comorbid diseases. For example, the risk of major complications following THA was about 17 times greater for patients with clotting abnormalities, nine times greater for those with paralysis, and nearly eight times greater for those with pulmonary circulation disorders.
For mortality, the strongest risk factors were metastatic cancer, pulmonary circulation disorders, alcohol abuse, paralysis, or congestive heart failure. For major and minor complications as well as mortality, risk increased with each additional year of age, with the greatest increase among nonagenarians.
Complications had a major impact on mortality rate. One year after THA, survival rate was 94.4% for nonagenarians without any major complications versus 79.8% for those with major complications.
Even for patients with complications, mortality rates for nonagenarians undergoing THA were lower than in the general population of people in their nineties. "We believe that this was most likely because elderly patients who become candidates for elective THA are healthier and biologically younger than the reference group of the general population; the resulting selection bias would be expected to lower the mortality of the nonagenarians in the study cohort," the researchers write.
The findings lend new insights into the safety of elective THA for nonagenarians. While complication and mortality rates are higher than in younger age groups, those risks may be minimized by "careful patient selection and adequate preparation." Dr. Leopold and colleagues conclude: "[E]lective THA can be appropriately considered by surgeons and patients when symptoms of hip osteoarthritis are present."
Read [Is Elective Total Hip Arthroplasty Safe in Nonagenarians: An Arthroplasty Registry Analysis]
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit https://www.wolterskluwer.com/en/health and follow us on LinkedIn and Twitter @WKHealth.
###
About The Journal of Bone & Joint Surgery
The Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in professional information, software solutions, and services for the healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2022 annual revenues of €5.5 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 20,900 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit www.wolterskluwer.com, follow us on LinkedIn, Twitter, Facebook, and YouTube.
Journal
Journal of Bone and Joint Surgery
Article Publication Date
25-Aug-2023